| Literature DB >> 28428928 |
Brandon Michael Henry1, Matthew J Graves1, Jakub R Pękala1, Beatrice Sanna2, Wan Chin Hsieh3, R Shane Tubbs4, Jerzy A Walocha1, Krzysztof A Tomaszewski1.
Abstract
The intercostobrachial nerve (ICBN), which usually originates from the lateral cutaneous branch of the second intercostal nerve, innervates areas of the axilla, lateral chest, and medial arm. It is at risk for injury during operative procedures that are often used in the management of breast cancer and such injury has been associated with postoperative sensory loss and neuropathic pain, decreasing the quality of life. PubMed, Excerpta Medica Database (EMBASE), ScienceDirect, Google Scholar, China National Knowledge Infrastructure (CNKI), Scientific Electronic Library Online (SciELO), Biosciences Information Service (BIOSIS), and Web of Science were searched comprehensively. Data concerning the prevalence, branching, origin and communications of the ICBN were extracted and pooled into a meta-analysis. A total of 16 studies (1,567 axillas) reported data indicating that the ICBN was present in 98.4% of person. It most often (90.6%) originated from fibers at the T2 spinal level and commonly coursed in two branching patterns: as a single trunk in 47.0% of cases and as a bifurcating pattern in 42.2%. In the latter cases, the bifurcation was usually unequal (63.4%). Additionally, the ICBN presented with anastomosing communication to the brachial plexus in 41.3% of cases. The ICBN is a prevalent and variable structure at significant risk for injury during operative procedures of the axilla. In view of the postoperative pain and paresthesia experienced by patients following injury, surgeons need to exercise caution and aim to preserve the ICBN when possible. Ultimately, careful dissection and knowledge of ICBN anatomy could allow postoperative complications to be reduced and patient's quality of life increased.Entities:
Keywords: axillary dissection; breast cancer; intercostobrachial nerve; mastectomy; neuropathy; oncological surgery
Year: 2017 PMID: 28428928 PMCID: PMC5393909 DOI: 10.7759/cureus.1101
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
PRISMA 2009 checklist
Completed checklist for the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2009 guidelines
| Section/topic | # | Checklist item | Reported on page # |
| TITLE | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| INTRODUCTION | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 4-5 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4-5 |
| METHODS | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 6 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 6 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 6 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 6 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 6 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6-7 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 6-7 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | N/A |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 6-7 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | 7 |
Figure 1PRISMA flow chart of the study identification and inclusion in the meta-analysis
Characteristics of included studies
ICBN - intercostobrachial nerve
| Study | Country | Type | n = (# half-bodies studied) | # of half-bodies with ICBN (%) |
| O’Rourke 1999 | Australia | Cadaveric | 28 | 28 (100%) |
| Cunnick 2001 | United Kingdom | Operative | 50 | 45 (90%) |
| Wu 2001 | China | Operative | 204 | 203 (100%) |
| Yin 2004 | China | Cadaveric | 50 | 48 (96%) |
| Li 2005 | China | Cadaveric & Operative | 70 | 70 (100%) |
| Zhao 2005 | China | Operative | 151 | 151 (100%) |
| Ge 2006 | China | Cadaveric | 5 | 5 (100%) |
| Loukas 2006 | Grenada/USA | Cadaveric | 200 | 200 (100%) |
| Zhang 2006 | China | Operative | 216 | 207 (96%) |
| Zhao 2008 | China | Cadaveric | 32 | 31 (97%) |
| Verma 2009 | India | Operative | 69 | 69 (100%) |
| Khan 2012 | United Kingdom | Operative | 73 | 73 (100%) |
| Kubala 2013 | Czech Republic | Operative | 113 | 107 (95%) |
| Soares 2014 | Brazil | Operative | 100 | 99 (99%) |
| Zhu 2014 | China | Operative | 156 | 156 (100%) |
| Kumar 2016 | India | Operative | 50 | 50 (100%) |
Figure 2Forest plot for pooled prevalence of the intercostobrachial nerve
Prevalence of the intercostobrachial nerve in human axillas
| Category | # of studies (# of axillas) | Prevalence of ICBN: % (95% CI) | I2: % (95% CI)* |
| Overall | 16 (1567) | 98.4 (97.1-99.4) | 64.4 (39.3-79.1) |
| Cadaveric | 5 (315) | 98.3 (95.3-100) | 51.0 (0.0-82.0) |
| Operative | 10 (1182) | 98.3 (96.5-99.4) | 70.5 (43.5-84.5) |
| Asia | 10 (1003) | 98.6 (97.2-99.6) | 53.4 (4.7-77.2) |
| Europe | 3 (236) | 95.7 (88.6-100) | 80.5 (38.9-93.8) |
| Sensitivity (n≥100) | 7 (1140) | 98.6 (96.7-99.7) | 76.7 (51.4-88.9) |
Types of origin of the intercostobrachial nerve from the lateral cutaneous branches of the intercostal nerves (vertebral levels)
| Category | # of studies (# of nerves) | T1 % (95% CI) | T1 & T2 % (95% CI) | T1, T2, & T3 % (95% CI) | T2 % (95% CI) | T2 & T3 % (95% CI) | T3 % (95% CI) | T2, T3, & T4 % (95% CI) | I2: % (95% CI)* |
| Overall | 12 (922) | 0.8 (0.0-4.5) | 2.9 (0.0-8.8) | 1.1 (0.0-5.1) | 90.6 (83.1-98.7) | 3.4 (0.0-9.7) | 0.6 (0.0-4.0) | 0.6 (0.0-4.0) | 94.3 (91.8-96.1) |
| Cadaveric | 5 (312) | 0.8 (0.0-13.9) | 1.4 (0.0-16.2) | 0.8 (0.0-13.9) | 88.3 (68.4-100) | 6.4 (0.0-29.7) | 0.8 (0.0-13.9) | 1.4 (0.0-16.0) | 95.8 (92.8-97.6) |
| Operative | 7 (568) | 1.0 0.0-3.6) | 4.9 (1.2-10.6) | 1.5 (0.0-4.5) | 89.7 (82.6-95.4) | 2.0 (0.0-6.3) | 0.6 (0.0-2.8) | 0.4 (0.0-2.2) | 82.9 (66.1-91.3) |
| Asia | 8 (576) | 1.0 (0.0-5.3) | 3.2 (0.0-9.7) | 1.5 (0.0-6.3) | 92.0 (87.5-100) | 1.3 (0.0-5.8) | 0.5 (0.0-3.7) | 0.5 (0.0-3.7) | 91.1 (85.0-94.8) |
| Europe | 2 (118) | 0.4 (0.0-7.4) | 3.4 (0.0-16.0) | 0.4 (0.0-7.4) | 90.5 (71.8-100) | 3.2 (0.0-15.5) | 1.7 (0.0-11.8) | 0.4 (0.0-7.4) | 86.7 (47.8-96.6) |
| Sensitivity (n≥100) | 3 (503) | 1.4 (0.0-15.6) | 5.4 (0.0-26.1) | 2.8 (0.0-19.8) | 76.8 (38.9-98.8) | 12.9 (0.0-39.8) | 0.6 (0.0-12.2) | 0.2 (0.0-9.3) | 98.2 (96.8-99.0) |
Branching patterns of the intercostobrachial nerve
| Category | # of studies (# of nerves) | Single Trunk % (95% CI) | Unification of two branches into Single Trunk % (95% CI) | Unification of two branches into Single Trunk with Re-Branching % (95% CI) | Total Bifurcation % (95% CI) | Multiple Branches % (95% CI) | I2: % (95% CI)* |
| Overall | 12 (1234) | 47.0 (23.8-67.9) | 2.7 (0.0-12.0) | 0.6 (0.0-6.5) | 42.2 (19.8-63.4) | 7.5 (0.0-20.8) | 98.2 (97.7-98.6) |
| Cadaveric | 4 (284) | 23.9 (0.0-75.9) | 2.9 (0.0-35.2) | 0.9 (0.0-26.4) | 65.3 (13.6-100) | 7.0 (0.0-46.9) | 97.6 (96.0-98.6) |
| Operative | 8 (950) | 59.2 (27.4-83.1) | 2.5 (0.0-15.0) | 0.5 (0.0-8.5) | 30.2 (6.3-57.6) | 7.6 (0.0-25.3) | 98.6 (98.1-98.9) |
| Asia | 9 (916) | 39.9 (11.8-69.3) | 1.2 (0.0-12.1) | 0.5 (0.0-9.3) | 50.5 (19.7-78.5) | 7.9 (0.0-27.2) | 98.6 (98.1-98.9) |
| Europe | 2 (118) | 60.3 (25.8-89.6) | 9.5 (0.0-33.0) | 1.7 (0.0-15.6) | 23.3 (1.0-56.5) | 5.3 (0.0-24.8) | 91.4 (70.0-97.5) |
| Sensitivity (n ≥100) | 5 (913) | 61.8 (19.0-93.8) | 0.9 (0.0-16.3) | 0.1 (0.0-11.4) | 29.1 (0.0-65.6) | 7.9 (0.0-34.7) | 99.2 (98.9-99.4) |
Figure 3Cadaver displaying a single trunk intercostobrachial nerve
Figure 4Cadaver displaying a bifurcating intercostobrachial nerve